Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 20

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
667)$2,184 

Common StockAdditional Paid in CapitalAccumulated DeficitStockholders’ EquitySharesAmount Balances at December 31, 202313,709,377$1 $63,676 $(50,515)$13,162  Exercise of warrants2,500- 8 - 8  Stock-based compensation expense -- 1,155 - 1,155  Net loss -- - (4,603)(4,603) Balances at March 31, 202413,711,877$1 $64,839 $(55,118)$9,722  Exercise of options1,000- 3 - 3  Stock-based compensation expense -- 591 - 591  Net loss -- - (4,971)(4,971) Balances at June 30, 202413,712,877$1 $65,433 $(60,089)$5,345 

The accompanying notes are an integral part of these condensed financial statements.

3

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

Six Months Ended June 30,20252024Cash flows from operating activities:Net loss$(5,884)$(9,574)Adjustments to reconcile net loss to net cash used in operating activities:Change in carrying value of right-of-use asset13 12 Stock-based compensation expense1,079 1,746 Changes in operating assets and liabilities, net:Accrued interest on marketable debt securities- (117)Prepaid expenses, other current assets, and other assets(47)157 Accounts payable, accrued expenses and other liabilities394 (804)Net cash used in operating activities(4,445)(8,580)Cash flows from investing activities:Purchase of marketable debt securities- (3,056)Redemption of marketable debt securities- 6,310 Net cash provided by investing activities- 3,254 Cash flows from financing activities:Proceeds from public offerings4,652 - Issuance costs related to public offerings(933)- Proceeds from ATM offerings345 - Issuance costs related to ATM offerings(17)- Proceeds from common stock issuances24 - Proceeds from exercise of warrants and options- 11 Net cash provided by